Volume 24, Issue 4 (July - August 2025)
Payesh 2025, 24(4): 563-573 |
Back to browse issues page
Ethics code: IR.MUMS.MEDICAL.REC.1400.436
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hashemian A M, Raoufinia R, RashidTorabi Z, Hajali V, Ghavidel Yazdi S, Saburi E. The relationship between rs4986790 polymorphism in TLR4 gene and its association with severity of the COVID-19. Payesh 2025; 24 (4) :563-573
URL: http://payeshjournal.ir/article-1-2512-en.html
URL: http://payeshjournal.ir/article-1-2512-en.html
Amir Masoud Hashemian1 
, Ramin Raoufinia2 , Zahra RashidTorabi3 , Vahid Hajali4 , Somayeh Ghavidel Yazdi5 , Ehsan Saburi *6
, Ramin Raoufinia2 , Zahra RashidTorabi3 , Vahid Hajali4 , Somayeh Ghavidel Yazdi5 , Ehsan Saburi *6
1- Department of emergency medicine, faculty of medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2- Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran
3- Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4- Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5- Samen Health center, Mashhad University of Medical Sciences, Mashhad, Iran
6- Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2- Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran
3- Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4- Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5- Samen Health center, Mashhad University of Medical Sciences, Mashhad, Iran
6- Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract: (50 Views)
Objective(s): Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to severe respiratory illnesses and fatalities in both young and elderly individuals without underlying diseases; however, similar groups may also include individuals who are asymptomatic or exhibit mild symptoms. Various studies have indicated that host genetics play a significant role in the severity of diseases caused by SARS-CoV-1 and MERS-CoV, which share substantial similarities with SARS-CoV-2. One of the crucial host genetic factors involved in identifying patterns of disease-causing agents and activating the innate immune system's Toll-like receptors (TLRs) is TLR4, which shows the strongest association with surface markers of SARS-CoV-2. This study was designed to investigate the common polymorphism of the TLR4 gene (Asp299Gly) to examine the relationship between disease severity and the presence of this polymorphism.
Methods: A total of 230 COVID-19 patients, comprising 154 patients with mild COVID-19 and 76 patients with severe COVID-19, were randomly selected and matched for age and gender from individuals referred to COVID-19 healthcare centers. Peripheral blood samples of 5 mL were obtained from the patients, and DNA was extracted for the analysis of the Asp299Gly-TLR4 polymorphism using the Tetra-ARMS PCR technique.
Results: The study revealed that 67% of the patients belonged to the mild COVID-19 group, while 33% were in the severe COVID-19 group. The analysis showed no significant correlation between disease severity and the Asp299Gly-TLR4 polymorphism. The frequencies of alleles and genotypes did not exhibit a significant relationship with disease severity in either the mild or severe COVID-19 groups.
Conclusion: The findings suggest that there is no significant association between the severity of COVID-19 and the rs4986790 polymorphism in the TLR4 gene. However, further investigation with larger sample sizes is warranted to confirm the effects of different TLR4 polymorphisms on the severity of COVID-19.
Methods: A total of 230 COVID-19 patients, comprising 154 patients with mild COVID-19 and 76 patients with severe COVID-19, were randomly selected and matched for age and gender from individuals referred to COVID-19 healthcare centers. Peripheral blood samples of 5 mL were obtained from the patients, and DNA was extracted for the analysis of the Asp299Gly-TLR4 polymorphism using the Tetra-ARMS PCR technique.
Results: The study revealed that 67% of the patients belonged to the mild COVID-19 group, while 33% were in the severe COVID-19 group. The analysis showed no significant correlation between disease severity and the Asp299Gly-TLR4 polymorphism. The frequencies of alleles and genotypes did not exhibit a significant relationship with disease severity in either the mild or severe COVID-19 groups.
Conclusion: The findings suggest that there is no significant association between the severity of COVID-19 and the rs4986790 polymorphism in the TLR4 gene. However, further investigation with larger sample sizes is warranted to confirm the effects of different TLR4 polymorphisms on the severity of COVID-19.
type of study: Case-control |
Subject:
Social Determinants of Health
Received: 2024/04/25 | Accepted: 2025/06/28 | ePublished ahead of print: 2025/09/9 | Published: 2025/09/9
Received: 2024/04/25 | Accepted: 2025/06/28 | ePublished ahead of print: 2025/09/9 | Published: 2025/09/9
References
1. Khanmohammadi S, Rezaei N. Role of Toll‐like receptors in the pathogenesis of COVID‐19. Journal Of Medical Virology 2021;93:2735-9 [DOI:10.1002/jmv.26826]
2. McIntosh K, Hirsch MS, Bloom A. COVID-19: Epidemiology, virology, and prevention. UpToDate Available online: https://www uptodate com/contents/covid-19-epidemiology-virology-and-prevention (accessed on 18 March 2021) 2021
3. WHO. Coronavirus disease 2019 (COVID-19) Situation Report - 78. 2020 [cited 2020 7 April]; Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200407-sitrep-78-covid-19.pdf?sfvrsn=bc43e1b_24
4. Stringhini S, Zaballa ME, Pullen N, Perez-Saez J, de Mestral C, Loizeau AJ, et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Eurosurveillance 2021;26: 2100830 [DOI:10.2807/1560-7917.ES.2021.26.43.2100830]
5. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine 2020; 180:1576-1586 [DOI:10.1001/jamainternmed.2020.4130]
6. Sabouri E, Saburi A, Gerami R, Zeraati T, Saburi E, Ghanei M. Computerized Intelligence and Mathematical Models for COVID-19 Diagnosis: A Review. Journal of Human Environment and Health Promotion 2023;9:55-62 [DOI:10.61186/jhehp.9.2.55]
7. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 2020;395:514-23 [DOI:10.1016/S0140-6736(20)30154-9]
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497-506 [DOI:10.1016/S0140-6736(20)30183-5]
9. Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Le Infezioni in Medicina 2021;29:20-3610
10. Payvar B, Azami S, Khodadadegan M, Saburi E, Sahab Negah S, Hajali V. Clinical Symptoms of COVID-19 Patients admitted to Hazrat Musa Ibne Jafar Hospital in Quchan City. Navid No 2022;25:11-7 [Persian]
11. World Health Organization. (2020). Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization. https://iris.who.int/handle/10665/332196. License: CC BY-NC-SA 3.0 IGO [DOI:10.15557/PiMR.2020.0004]
12. Rashedi J, Mahdavi Poor B, Asgharzadeh V, Pourostadi M, Samadi Kafil H, Vegari A, et al. Risk factors for COVID-19. Le Infezioni in Medicina 2020;28:469-74
13. Arab F, Mollazadeh S, Ghayourbabaei F, Moghbeli M, Saburi E. The role of HLA genotypes in understanding the pathogenesis of severe COVID-19. Egyptian Journal of Medical Human Genetics 2023;24:14 [DOI:10.1186/s43042-023-00392-3]
14. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature Reviews Immunology 2020;20:355-62 [DOI:10.1038/s41577-020-0331-4]
15. Saburi E, Abazari MF, Hassannia H, Mansour RN, Eshaghi-Gorji R, Gheibi M, et al. The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19. Gene 2021;20:777:145471 [DOI:10.1016/j.gene.2021.145471]
16. Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs. Journal Of Medical Virology 2020;92:2105-13 [DOI:10.1002/jmv.25987]
17. Shirato K, Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon 2021;7:2 [DOI:10.1016/j.heliyon.2021.e06187]
18. Jungi TW, Farhat K, Burgener IA, Werling D. Toll-like receptors in domestic animals. Cell and Tissue Research 2011;343:107-20 [DOI:10.1007/s00441-010-1047-8]
19. Bisyuk ya. tlr-4 gene polymorphism (asp299gly) in adult patients with atopic and non-atopic bronchial asthma in the crimea population. Pulmonologiya 2014:68-72 [DOI:10.18093/0869-0189-2014-0-3-68-72]
20. Barbarash O, Golovkin A, Ponasenko A, Kutikhin A, Zhidkova I, Khutornaya M, et al. The role of Toll-like receptors polymorphism in atherosclerosis complications development. Russian Journal of Cardiology 2015:36:72-9
21. Bogodukhovа E, Bаyke E. Polymorphism of genes of Toll-like receptors as a potential factor of predisposition to tuberculosis. Tuberculosis and Lung Diseases 2018;96:11-6 [DOI:10.21292/2075-1230-2018-96-9-11-16]
22. Zacher C, Schönfelder K, Rohn H, Siffert W, Möhlendick B. The single nucleotide polymorphism rs4986790 (c. 896A> G) in the gene TLR4 as a protective factor in corona virus disease 2019 (COVID-19). Frontiers In Immunology 2024;15:1355193 [DOI:10.3389/fimmu.2024.1355193]
23. Flores-Gonzalez J, Chavez-Galan L, Falfán-Valencia R, Roldán IB, Fricke-Galindo I, Veronica-Aguilar A, et al. Variant rs4986790 of toll-like receptor 4 affects the signaling and induces cell dysfunction in patients with severe COVID-19. International Journal of Infectious Diseases 2024;138:102-9 [DOI:10.1016/j.ijid.2023.11.032]
24. Bakaros E, Voulgaridi I, Paliatsa V, Gatselis N, Germanidis G, Asvestopoulou E, et al. Innate immune gene polymorphisms and COVID-19 prognosis. Viruses 2023;15:1784 [DOI:10.3390/v15091784]
25. Tulic MK, Hurrelbrink RJ, Prêle CM, Laing IA, Upham JW, Le Souef P, et al. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. The Journal of Immunology 2007;179:132-40 [DOI:10.4049/jimmunol.179.1.132]
26. Kresfelder T, Janssen R, Bont L, Venter M. Confirmation of an association between single nucleotide polymorphisms in the VDR gene with respiratory syncytial virus related disease in South African children. Journal Of Medical Virology 2011;83:1834-40 [DOI:10.1002/jmv.22179]
27. Esposito S, Molteni CG, Giliani S, Mazza C, Scala A, Tagliaferri L, et al. Toll-like receptor 3 gene polymorphisms and severity of pandemic A/H1N1/2009 influenza in otherwise healthy children. Virology Journal 2012;9:1-8 [DOI:10.1186/1743-422X-9-270]
28. Malyarchikov A, Shapovalov K. The role of Toll-like receptor 4 gene polymorphism in the development of organ dysfunction in patients with severe pneumonia associated with A/H1N1 influenza. Acta Biomedica Scientifica 2023;8:79-85 [DOI:10.29413/ABS.2023-8.1.9]
29. Taha SI, Shata AK, Baioumy SA, Fouad SH, Anis SG, Mossad IM, et al. Toll-like receptor 4 polymorphisms (896A/G and 1196C/T) as an indicator of COVID-19 severity in a convenience sample of Egyptian patients. Journal of Inflammation Research 2021;14:6293 [DOI:10.2147/JIR.S343246]
30. Taha SI, Shata AK, El-Sehsah EM, Mohamed MF, Moustafa NM, Youssef MK. Comparison of COVID-19 characteristics in Egyptian patients according to their Toll-Like Receptor-4 (Asp299Gly) polymorphism. Le Infezioni in Medicina 2022;30:96 [DOI:10.53854/liim-3001-11]
31. Salamaikina S, Karnaushkina M, Korchagin V, Litvinova M, Mironov K, Akimkin V. TLRs Gene Polymorphisms Associated with Pneumonia before and during COVID-19 Pandemic. Diagnostics 2022;13:121 [DOI:10.3390/diagnostics13010121]
32. Hajali V, Payvar B, Fattahi A, Izadpanah K, Esfahani H, Saburi E, et al. Clinical and Laboratory Characteristics of Hospitalized Patients With COVID-19 After Vaccination in Quchan-Iran. Research in Molecular Medicine 2023;11:57-66 [DOI:10.32598/rmm.11.1.1277.2]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |